Bioactive Metabolites: A Clue to the Link Between MASLD and CKD?

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2024 Oct 21

PMID 39428978

Authors

Wen-Ying Chen

Jia-Hui Zhang

Li-Li Chen

Christopher D Byrne

Giovanni Targher

Liang Luo

Yan Ni

Ming-Hua Zheng

Dan-Qin Sun

Affiliations

Soon will be listed here.

Abstract

Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the bacterial metabolism of dietary substrates, modification of host molecules (such as bile acids [BAs], trimethylamine-N-oxide, and short-chain fatty acids), or products directly derived from bacteria. Recent studies have provided new insights into the association between MASLD and the risk of developing chronic kidney disease (CKD). Furthermore, alterations in microbiota composition and metabolite profiles, notably altered BAs, have been described in studies investigating the association between MASLD and the risk of CKD. This narrative review discusses alterations of specific classes of metabolites, BAs, fructose, vitamin D, and microbiota composition that may be implicated in the link between MASLD and CKD.

References

Wong V, Tse C, Lam T, Wong G, Chim A, Chu W . Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. PLoS One. 2013; 8(4):e62885. PMC: 3636208. DOI: 10.1371/journal.pone.0062885. View

Sun D, Jin Y, Wang T, Zheng K, Rios R, Zhang H . MAFLD and risk of CKD. Metabolism. 2020; 115:154433. DOI: 10.1016/j.metabol.2020.154433. View

Lin K, Dong C, Zhao B, Zhou B, Yang L . Glucagon-like peptide-1 receptor agonist regulates fat browning by altering the gut microbiota and ceramide metabolism. MedComm (2020). 2023; 4(6):e416. PMC: 10661313. DOI: 10.1002/mco2.416. View

Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A . Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017; 25(5):1054-1062.e5. PMC: 5502730. DOI: 10.1016/j.cmet.2017.04.001. View

Billing A, Kim Y, Gullaksen S, Schrage B, Raabe J, Hutzfeldt A . Metabolic Communication by SGLT2 Inhibition. Circulation. 2023; 149(11):860-884. PMC: 10922673. DOI: 10.1161/CIRCULATIONAHA.123.065517. View

Li H, Xi Y, Xin X, Tian H, Hu Y . Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis. Biomed Pharmacother. 2020; 124:109915. DOI: 10.1016/j.biopha.2020.109915. View

Rahman K, Desai C, Iyer S, Thorn N, Kumar P, Liu Y . Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Gastroenterology. 2016; 151(4):733-746.e12. PMC: 5037035. DOI: 10.1053/j.gastro.2016.06.022. View

Byrne C, Targher G . NAFLD as a driver of chronic kidney disease. J Hepatol. 2020; 72(4):785-801. DOI: 10.1016/j.jhep.2020.01.013. View

Oh T, Kim S, Caussy C, Fu T, Guo J, Bassirian S . A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell Metab. 2020; 32(5):901. PMC: 7891106. DOI: 10.1016/j.cmet.2020.10.015. View

Koshida T, Gohda T, Sugimoto T, Asahara T, Asao R, Ohsawa I . Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease. Int J Mol Sci. 2023; 24(14). PMC: 10380578. DOI: 10.3390/ijms241411456. View

10.

Kitson M, Roberts S . D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol. 2012; 57(4):897-909. DOI: 10.1016/j.jhep.2012.04.033. View

11.

Jiao N, Baker S, Chapa-Rodriguez A, Liu W, Nugent C, Tsompana M . Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2017; 67(10):1881-1891. DOI: 10.1136/gutjnl-2017-314307. View

12.

Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette J, Diehl A . Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008; 48(6):993-9. PMC: 2423467. DOI: 10.1016/j.jhep.2008.02.011. View

13.

Grasset E, Puel A, Charpentier J, Collet X, Christensen J, Terce F . A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metab. 2017; 25(5):1075-1090.e5. DOI: 10.1016/j.cmet.2017.04.013. View

13.

Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A . Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2019; 30(3):607. PMC: 8025688. DOI: 10.1016/j.cmet.2019.08.002. View

14.

Schaap F, Trauner M, Jansen P . Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2013; 11(1):55-67. DOI: 10.1038/nrgastro.2013.151. View

15.

Clark D . The fermentation pathways of Escherichia coli. FEMS Microbiol Rev. 1989; 5(3):223-34. DOI: 10.1016/0168-6445(89)90033-8. View

16.

Goldsmith D, Cunningham J . Mineral metabolism and vitamin D in chronic kidney disease--more questions than answers. Nat Rev Nephrol. 2011; 7(6):341-6. DOI: 10.1038/nrneph.2011.53. View

17.

Deng Y, Wang H, Lu Y, Liu S, Zhang Q, Huang J . Identification of chemerin as a novel FXR target gene down-regulated in the progression of nonalcoholic steatohepatitis. Endocrinology. 2013; 154(5):1794-801. DOI: 10.1210/en.2012-2126. View

18.

Da Silva H, Teterina A, Comelli E, Taibi A, Arendt B, Fischer S . Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018; 8(1):1466. PMC: 5780381. DOI: 10.1038/s41598-018-19753-9. View